When a coronary artery is opened with a stent, the vessel wall responds to that mechanical injury the way tissue generally responds to injury anywhere in the body: it tries to heal, sometimes too enthusiastically. A sirolimus eluting stent is designed specifically to manage that healing response so the artery does not re-narrow. Understanding how sirolimus works at a cellular level helps explain why drug-eluting stents replaced bare-metal designs as the dominant technology in percutaneous coronary intervention, and why coating chemistry remains an active area of device engineering.
What Causes Restenosis After Stent Placement?
Restenosis is the gradual re-narrowing of a treated artery segment, generally attributed to a process called neointimal hyperplasia. After a stent is deployed, the vessel wall is stretched and, in some cases, mildly injured. Smooth muscle cells in the arterial wall respond by migrating and proliferating, laying down new tissue over the stent struts. Some of this tissue growth is desirable, since it helps the stent become incorporated into the vessel wall. Excessive growth, however, can narrow the lumen again and restrict blood flow, which is the underlying concern that drug-eluting stent technology was developed to address.
How Does Sirolimus Limit Cell Proliferation?
Sirolimus belongs to a class of compounds generally referred to as mTOR inhibitors. mTOR (mechanistic target of rapamycin) is a protein that helps regulate cell growth and division. By inhibiting this pathway, sirolimus is understood to slow the proliferation and migration of smooth muscle cells at the treatment site, which in turn is intended to limit the amount of neointimal tissue that forms over time. This is a localized, targeted effect rather than a systemic one, since the drug is delivered directly from the stent surface to the adjacent vessel wall rather than through oral or intravenous administration.
Controlled Drug Elution From the Stent Coating
A drug-eluting stent works by combining a metal scaffold with a polymer coating that holds the antiproliferative drug and releases it gradually after implantation. The elution profile, meaning how much drug is released and over what time period, is engineered so that therapeutic drug levels are maintained at the vessel wall during the weeks when neointimal proliferation risk is generally considered highest. Coating chemistry, drug dose per unit of stent surface area, and polymer composition all influence this release kinetics profile, which is why manufacturers report these parameters as part of a device's technical specification.
The ATLAS System's Sirolimus Coating
The ATLAS Drug Eluting Coronary Stent System, manufactured by INVAMED, is built on a cobalt-chromium platform and carries a sirolimus coating reported by the manufacturer at 1 µg/mm² of stent surface area. The device combines this coating with a thin-strut cobalt-chromium L605 alloy frame, which the manufacturer describes as supporting durable radial strength and trackability in complex or calcified coronary lesions. Additional technical detail, along with the complete Instructions for Use (IFU), is available on the ATLAS Drug Eluting Coronary Stent System product page. Availability and specific indications vary by country, and clinicians should always consult the IFU before use.
Sirolimus Compared With Other Antiproliferative Agents
Sirolimus is one of several antiproliferative agents used across the drug-eluting stent category. Other limus-family compounds are used in various commercial DES platforms, and paclitaxel, a different class of antiproliferative drug, is also used in some coronary stent and balloon technologies. Each agent has its own mechanism nuances and elution characteristics, and device selection in clinical practice depends on lesion characteristics, vessel size, and the treating physician's assessment rather than on a single drug class being universally preferred. A qualified physician determines which device and drug platform is suitable for an individual patient's coronary anatomy.
Is sirolimus the same as other limus drugs used in stents?
Sirolimus is the original compound in a broader family of related mTOR inhibitors sometimes described collectively as "limus" drugs. These compounds share a similar general mechanism of limiting cell proliferation but can differ in molecular structure, potency, and release characteristics depending on the specific stent platform.
How long does a stent continue releasing its drug coating?
Elution timelines vary by device and are defined by each manufacturer's coating design and polymer composition. Specific release duration for a given stent should be confirmed in that product's Instructions for Use rather than assumed from general category information.
Does a sirolimus eluting stent eliminate the risk of restenosis entirely?
No device eliminates restenosis risk entirely. Drug-eluting stents are designed to reduce the likelihood of significant neointimal overgrowth compared with bare-metal designs, but individual outcomes depend on factors including lesion complexity, vessel size, and patient-specific healing response. A qualified physician evaluates these factors when recommending a treatment approach.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.